Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunkai Qie

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Oncotargets and Therapy|February 13, 2016
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective studyYu Zhang, Linguo Xie, Tao Chen, et al.
International Journal of Molecular Sciences|October 28, 2014
Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese populationYu Zhang, Yan Sun, Tao Chen, et al.
Scientific Reports|May 29, 2025
Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: a multicenter retrospective studyShiwang Huang, Kaipeng Jia, Jingmin Cui, et al.
Frontiers in Oncology|October 27, 2022
Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancerChong Shen, Zhi Li, Yinglang Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 7, 2022
Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted NanodrugBozhao Li, Xiuping Zhang, Zhouliang Wu, et al.
Cancer|June 24, 2026
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxelShiwang Huang, Kaipeng Jia, Shan Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2025
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder CancerYunkai Qie, Shiwang Huang, Chong Shen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Oncotargets and Therapy|February 13, 2016
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective studyYu Zhang, Linguo Xie, Tao Chen, et al.
International Journal of Molecular Sciences|October 28, 2014
Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese populationYu Zhang, Yan Sun, Tao Chen, et al.
Scientific Reports|May 29, 2025
Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: a multicenter retrospective studyShiwang Huang, Kaipeng Jia, Jingmin Cui, et al.
Frontiers in Oncology|October 27, 2022
Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancerChong Shen, Zhi Li, Yinglang Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 7, 2022
Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted NanodrugBozhao Li, Xiuping Zhang, Zhouliang Wu, et al.
Cancer|June 24, 2026
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxelShiwang Huang, Kaipeng Jia, Shan Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2025
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder CancerYunkai Qie, Shiwang Huang, Chong Shen, et al.
Pageof 3